Comparison of the myocardial blood flow response to regadenoson and dipyridamole: A quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 10, 2011, Pages 1908-1916

  Goudarzi, Behnaz ^a   Fukushima, Kenji ^a   Bravo, Paco ^a   Merrill, Jennifer ^a   Bengel, Frank M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Coronary artery disease; Myocardial flow reserve; PET; Pharmacological vasodilation; Regadenoson

Indexed keywords

AMINOPHYLLINE; DIPYRIDAMOLE; REGADENOSON; RUBIDIUM 82;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIZZINESS; DRUG INDUCED HEADACHE; DYSPNEA; FEMALE; HEART MUSCLE BLOOD FLOW; HEART MUSCLE PERFUSION; HEART PALPITATION; HEART RATE; HEMODYNAMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT REFERRAL; PHARMACOLOGIC STRESS TESTING; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; VASODILATATION;

CORONARY CIRCULATION; DIPYRIDAMOLE; FEMALE; HEMODYNAMICS; HUMANS; INJECTIONS; MALE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; PURINERGIC P1 RECEPTOR AGONISTS; PURINES; PYRAZOLES; RETROSPECTIVE STUDIES; RUBIDIUM RADIOISOTOPES; STRESS, PHYSIOLOGICAL;

EID: 80455174780     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1853-6     Document Type: Article

References (24)

1. Bengel FM, Higuchi T, Javadi MS, Lautamaki R. Cardiac positron emission tomography. J Am Coll Cardiol. 2009;54(1):1-15.
2. Di Carli MF, Hachamovitch R. New technology for noninvasive evaluation of coronary artery disease. Circulation. 2007;115(11):1464-80. (Pubitemid 46648384)
3. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99 m sestamibi SPECT. J Nucl Cardiol. 2006;13(1):24-33. (Pubitemid 43192726)
4. Gould KL, Ornish D, Scherwitz L, Brown S, Edens RP, Hess MJ, et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA. 1995;274(11):894-901.
5. Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol. 2008;15(6):745-53.
6. Yoshinaga K, Chow BJ, Williams K, Chen L, de Kemp RA, Garrard L, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol. 2006;48(5):1029-39. (Pubitemid 44292462)
7. Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol. 1994;23(2):384-9. (Pubitemid 24049369)
8. Al Jaroudi W, Iskandrian AE. Regadenoson: a new myocardial stress agent. J Am Coll Cardiol. 2009;54(13):1123-30.
9. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging. 2008;1(3):307-16. (Pubitemid 351676842)
10. Hendel RC, Bateman TM, Cerqueira MD, Iskandrian AE, Leppo JA, Blackburn B, et al. Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging. J Am Coll Cardiol. 2005;46(11):2069-75. (Pubitemid 41713594)
11. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol. 2007;14(5):645-58. (Pubitemid 47355078)
12. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging. 2009;2(8):959-68.
13. Lautamaki R, Brown TL, Merrill J, Bengel FM. CT-based attenuation correction in (82) Rb-myocardial perfusion PET-CT: incidence of misalignment and effect on regional tracer distribution. Eur J Nucl Med Mol Imaging. 2008;35(2):305-10.
14. Bravo PE, Chien D, Javadi M, Merrill J, Bengel FM. Reference ranges for LVEF and LV volumes from electrocardiographically gated 82Rb cardiac PET/CT using commercially available software. J Nucl Med. 2010;51(6):898-905.
15. Chander A, Brenner M, Lautamaki R, Voicu C, Merrill J, Bengel FM. Comparison of measures of left ventricular function from electrocardiographically gated 82Rb PET with contrast-enhanced CT ventriculography: a hybrid PET/CT analysis. J Nucl Med. 2008;49(10):1643-50.
16. Nekolla SG, Miethaner C, Nguyen N, Ziegler SI, Schwaiger M. Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography. Eur J Nucl Med. 1998;25(9):1313-21. (Pubitemid 28446059)
17. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-ammonia. J Nucl Med. 1996;37(10):1701-12. (Pubitemid 26337184)
18. Lautamaki R, George RT, Kitagawa K, Higuchi T, Merrill J, Voicu C, et al. Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis. Eur J Nucl Med Mol Imaging. 2009;36(4):576-86.
19. Czernin J, Muller P, Chan S, Brunken RC, Porenta G, Krivokapich J, et al. Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation. 1993;88:62-9. (Pubitemid 23195433)
20. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebocontrolled trial. J Nucl Cardiol. 2008;15(3):329-36.
21. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol. 2008;15(3):319-28.
22. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol. 2007;14(4):514-20. (Pubitemid 47163555)
23. Gaemperli O, Schepis T, Koepfli P, Siegrist PT, Fleischman S, Nguyen P, et al. Interaction of caffeine with regadenosoninduced hyperemic myocardial blood flow as measured by positron emission tomography: a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol. 2008;51(3):328-9.
24. Dhalla AK, Wong MY, Wang WQ, Biaggioni I, Belardinelli L. Tachycardia caused by A2A adenosine receptor agonists is mediated by direct sympathoexcitation in awake rats. J Pharmacol Exp Ther. 2006;316(2):695-702. (Pubitemid 43130996)